30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Orthofix Enrolls First Patient in Knee OA Study -

Orthofix enrolled the first patient in a study evaluating use of Physio-Stim pulsed electromagnetic field (PEMF) technology to treat knee osteoarthritis (OA). Specifically, the study will assess the system in reducing inflammation and restoring homeostasis of the extracellular matrix, potentially providing symptomatic relief of OA pain, reducing cartilage breakdown and stimulating new cartilage formation.

The prospective, randomized, double-blind, placebo-controlled feasibility trial will enroll ~150 patients at 3 U.S. sites. If successful, this would be the first disease-modifying treatment for osteoarthritis.

Physio-Stim is approved by FDA for the treatment of nonunion fractures. Use in the OA study is investigational and is conducted under an Investigational Device Exemption.

At 1H16, OFIX reported Bone Stim segment growth at +9.4% vs. 1H15. Strength in net BioStim sales is expected to continue throughout 2016, though growth will return to mid-single-digits in the face of year-over-year comps.

Sources: Orthofix Int'l. N.V.; ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.